ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 Nuclear Energy Conference & Expo (NECX)
August 24–27, 2026
Dallas, TX|Hilton Anatole
Latest Magazine Issues
Jun 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
August 2026
Nuclear Technology
July 2026
Fusion Science and Technology
Latest News
Launching into tomorrow: NRIC guides new era of research and deployment
In June 2025, the Department of Energy announced the Reactor Pilot Program, an authorization pathway that allowed reactor developers to partner with the DOE to get first-of-a-kind (FOAK) reactors built and tested. Soon after, the DOE rolled out a complementary Fuel Line Pilot Program, which aimed to fast-track fuel projects. In all, 20 projects were accepted into the new programs.
Hungyuan B. Liu, Francis J. Patti
Nuclear Technology | Volume 116 | Number 3 | December 1996 | Pages 373-377
Technical Note | Heat Transfer and Fluid Flow | doi.org/10.13182/NT96-A35292
Articles are hosted by Taylor and Francis Online.
Recent changes are updated for the proposed modification to use a fission plate converter and a matching filter/moderator assembly in a newly designed beam shutter to enhance the epithermal neutron beam for patient irradiations during boron neutron capture therapy (BNCT) at the Brookhaven Medical Research Reactor, Brookhaven National Laboratory. Engineering design of the new beam shutter system has been completed, and design review is under way. With this upgrade, the epithermal neutron flux could be increased up to seven times higher than the present beam, and the fast-neutron dose per epithermal neutron fluence could be reduced to near half. Such an enhanced epithermal neutron beam would increase the effectiveness of clinical BNCT by allowing increased doses to the tumor with similar or lesser doses to normal tissues.